EU GMP Annex 11 & Draft Annex 22: Are BFS Manufacturers Ready?
The pharmaceutical industry is entering a new era of digital regulation.
With the proposed revisions to Annex 11 and the introduction of the draft Annex 22 for Artificial Intelligence, regulators are signalling a clear message: digital systems, data, cybersecurity and AI are now considered critical GMP responsibilities.
For those of us working in Blow Fill Seal (BFS), this isn't simply an IT discussion. It has direct implications for how we design, validate, operate and maintain our manufacturing environments.
Why This Matters for BFS
BFS facilities have always relied heavily on automation.
From SCADA systems and PLCs to environmental monitoring, vision inspection, electronic batch records and process historians, modern BFS operations generate vast amounts of critical GMP data.
Historically, many organisations focused primarily on validating software.
The direction of travel now appears broader.
Regulators increasingly expect manufacturers to demonstrate control over the entire digital ecosystem, including:
- Data governance
- Cybersecurity
- Supplier oversight
- Cloud-based services
- AI-driven systems
- Continuous monitoring and lifecycle management
The emphasis is shifting from simply validating software to governing digital processes.
Cybersecurity is Now Explicitly Part of GMP Expectations
One of the most significant developments is the increased focus on cybersecurity.
For BFS manufacturers, the potential impact of a cyber incident goes far beyond business disruption.
A compromised system could potentially affect:
- Critical process parameters
- Environmental monitoring records
- Batch data
- Audit trails
- Electronic signatures
- Product release decisions
This means Quality, Engineering and IT teams can no longer operate in isolation.
Cybersecurity is becoming a shared GMP responsibility that must be managed throughout the lifecycle of computerised systems.
AI is No Longer a Future Discussion
The draft Annex 22 is particularly interesting for the BFS sector.
Many organisations are already exploring AI applications such as:
- Predictive maintenance
- Vision inspection enhancement
- Process optimisation
- Yield improvement
- Trend analysis
- Deviation investigation support
The opportunity is enormous.
However, regulators are making it clear that AI systems used in GMP-regulated activities must be appropriately governed throughout their lifecycle.
Questions manufacturers will increasingly need to answer include:
- How was the model trained?
- What data was used?
- How is performance monitored?
- How are changes controlled?
- How do we ensure decisions remain explainable?
- When should revalidation be triggered?
These are likely to become familiar discussions for Quality and Validation teams over the coming years.
Cloud Adoption Continues to Grow
Many pharmaceutical manufacturers have already moved parts of their infrastructure into cloud environments.
The updated Annex 11 approach recognises this reality.
However, moving to the cloud does not transfer GMP responsibility to the service provider.
Manufacturers remain accountable for:
- Supplier qualification
- Service agreements
- Data integrity
- Security controls
- Business continuity
- Disaster recovery
In other words, GMP responsibility remains with the regulated company, regardless of how much infrastructure or software is outsourced.
Why BFS Manufacturers Should Pay Attention Now
Many BFS facilities already operate some of the most automated manufacturing environments in the pharmaceutical industry.
From machine control systems and environmental monitoring to vision inspection and electronic records, digital technologies are deeply embedded in day-to-day operations.
As regulatory expectations evolve, manufacturers that take a proactive approach to governance, validation, cybersecurity and data management will be better positioned to maintain compliance while taking advantage of emerging technologies such as AI and advanced analytics.
The question is no longer whether these technologies will be used in GMP environments.
The question is how they will be controlled.
Discussion
The consultation drafts for the revised Annex 11 and new Annex 22 were released by the European Commission to gather industry feedback and help shape the future regulatory framework for digital systems and AI in GMP environments.
Are BFS manufacturers ready?
Which area do you think will create the biggest challenge over the next five years?
🔹 Cybersecurity
🔹 AI Validation
🔹 Data Integrity & Governance
🔹 Cloud & Supplier Management
#BFS #BlowFillSeal #PharmaManufacturing #Annex11 #Annex22 #ArtificialIntelligence #DataIntegrity #CyberSecurity #GMP #PharmaceuticalIndustry #Validation #DigitalTransformation #AsepticProcessing #PharmaEngineering #QualityAssurance